Ingenium and ASINEX Announce Successful Lead Optimization Program
MUNICH and MOSCOW, June 6 /PRNewswire/ — Ingenium Pharmaceuticals AG, a drug discovery and development company, and ASINEX Ltd., a leading provider of lead generation and chemical optimization services, announced today a successful lead optimization project resulting in the generation of novel active compounds, which will expand Ingenium’s current proprietary pipeline of potential treatments for pain and inflammatory diseases. Due to the success of this completed project, the two companies will continue the collaboration throughout 2006.
Commenting on the agreement, Dr. Klaus Dembowsky, Ingenium’s Vice President of Drug Discovery, said, “As Ingenium continues to advance its drug discovery and development programs through preclinical pharmacological evaluation, effective lead optimization is critical. ASINEX has performed rapidly and efficiently to meet our needs and we have filed key patents based on these novel compounds.”
“We are looking forward to continuing our collaboration with Ingenium. After starting on a small scale, our relationship has grown over the last few months. We have successfully completed challenging tasks for Ingenium, and we are delighted that our work has made a positive impact on the company’s pipeline,” said Dr. Andrea Altieri, ASINEX’s Head of Project Management.
